EXOZYMES INC. Research and Development Expense
EXOZYMES INC. (EXOZ) reported Research and Development Expense of $1.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- EXOZYMES INC. research and development expense for the quarter ending 2026-06-30 was $1.44M, a 79.10% increase year-over-year.
- EXOZYMES INC. research and development expense for the quarter ending 2026-03-31 was $1.12M, a 94.95% increase year-over-year.
- EXOZYMES INC. research and development expense for the quarter ending 2025-12-31 was $1.11M, a 76.46% increase year-over-year.
- EXOZYMES INC. research and development expense for the quarter ending 2025-09-30 was $1.22M, a 68.18% increase year-over-year.
- EXOZYMES INC. research and development expense for fiscal 2025 was $3.71M, a 98.37% increase from fiscal 2024.
- EXOZYMES INC. research and development expense for fiscal 2024 was $1.87M, a 254.28% increase from fiscal 2023.
- EXOZYMES INC. research and development expense for fiscal 2023 was $527.48K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-13 | $2.56M 10-Q · filed 2026-08-13 | $3.67M derived: sum of 3 quarters · filed 2026-08-13 | $4.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.12M 10-Q · filed 2026-05-14 | $2.23M derived: sum of 2 quarters · filed 2026-05-14 | $3.45M derived: sum of 3 quarters · filed 2026-05-14 | $4.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.33M derived: sum of 2 quarters · filed 2026-03-30 | $3.13M derived: sum of 3 quarters · filed 2026-08-13 | $3.71M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.22M 10-Q · filed 2025-11-13 | $2.02M derived: sum of 2 quarters · filed 2026-08-13 | $2.59M 10-Q · filed 2025-11-13 | $3.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $802.99K 10-Q · filed 2026-08-13 | $1.38M 10-Q · filed 2026-08-13 | $2.01M derived: sum of 3 quarters · filed 2026-08-13 | $2.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $575.02K 10-Q · filed 2026-05-14 | $1.21M derived: sum of 2 quarters · filed 2026-05-14 | $1.93M derived: sum of 3 quarters · filed 2026-05-14 | $2.17M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $630.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.35M derived: sum of 2 quarters · filed 2026-03-30 | $1.59M derived: sum of 3 quarters · filed 2026-03-30 | $1.87M 10-K · filed 2026-03-30 |
| 2024-09-30 | $723.49K 10-Q · filed 2025-11-13 | $960.88K derived: sum of 2 quarters · filed 2025-11-13 | $1.24M 10-Q · filed 2025-11-13 | $1.70M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $237.40K 10-Q · filed 2025-08-12 | $514.98K 10-Q · filed 2025-08-12 | $975.36K derived: sum of 3 quarters · filed 2025-08-12 | $1.00M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $277.58K 10-Q · filed 2025-05-12 | $737.97K derived: sum of 2 quarters · filed 2025-05-12 | $765.90K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $460.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $488.32K derived: sum of 2 quarters · filed 2025-03-31 | $527.48K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $27.94K 10-Q · filed 2024-11-12 | $67.09K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |